Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers by Nooshafarin Shirani, Neda Abdi, Matin Chehelgerdi, Matin Chehelgerdi, Hajar Yaghoobi, Mohammad Chehelgerdi, Mohammad Chehelgerdi

“…Exosomes, as key mediators of intercellular communication, have been increasingly recognized for their role in the oncogenic processes, particularly in facilitating drug resistance. …”
Get full text

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer by Jun Sakakibara-Konishi, Hirofumi Takahashi, Kenichiro Ito, Tomoo Ikari, Yasuyuki Ikezawa, Hidenori Kitai, Megumi Furuta, Yuta Takashima, Tetsuaki Shoji, Masahide Fukudo, Satoshi Konno

“…Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1–2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearranged patients with NSCLC and shows mostly tolerable adverse events. …”
Get full text

Control of Herpesvirus Infection in Organ Transplant Recipients by Nina E Tolkoff-Rubin, Robert H Rubin

“…Because of their properties of latency, cell association, and potential oncogenicity, they are particularly well suited to causing disease in the transplant patient. …”
Get full text

Nrf2/cyclooxygenase 2 signaling in Cr(VI)-induced carcinogenesis by Lei Zhao, Yi-Fang Wang, Andrea Adamcakova-Dodd, Peter S. Thorne, Ranakul Islam, Ke Jian Liu, Fei Chen, Jia Luo, Ling-Zhi Liu

“…In summary, our study revealed the oncogenic role of COX-2 and identified two novel regulatory mechanisms for COX-2 overexpression in Cr(VI)-induced carcinogenesis.…”
Get full text

Helicobacter pylori: Genomic Insight into the Host-Pathogen Interaction by Kathryn P. Haley, Jennifer A. Gaddy

“…Perturbation of this coevolution results in dysregulation of the host-pathogen interaction, leading to oncogenic effects. This review discusses the relationship of H. pylori with the human host and environment and the contribution of each of these factors to disease progression, with an emphasis on features that have been illuminated by genomic tools.…”
Get full text

Plakoglobin: Role in Tumorigenesis and Metastasis by Zackie Aktary, Manijeh Pasdar

“…However, unlike β-catenin that has well-documented oncogenic potential through its involvement in the Wnt signaling pathway, plakoglobin generally acts as a tumor/metastasis suppressor. …”
Get full text

The Role of Exosomes in Cancer Progression and Therapy by Shynggys Sergazy, Roza Seydahmetova, Alexandr Gulyayev, Zarina Shulgau, Mohamad Aljofan

“…Interestingly, tumor-derived exosomes carry oncogenic molecules, such as proteins and microRNAs, which can reprogram recipient cells, promote angiogenesis, and stimulate cancer pre-metastatic niche, supporting cancer growth and metastasis. …”
Get full text

RNA Splicing: A New Player in the DNA Damage Response by Silvia C. Lenzken, Alessia Loffreda, Silvia M. L. Barabino

“…The observation that hereditary cancers are often characterized by mutations in DNA repair and checkpoint genes suggests that accumulation of DNA damage is a major contributor to the oncogenic transformation. It is therefore of great interest to identify all the cellular pathways that contribute to the response to DNA damage. …”
Get full text

Regulation of Skp2 Expression and Activity and Its Role in Cancer Progression by Chia-Hsin Chan, Szu-Wei Lee, Jing Wang, Hui-Kuan Lin

“…The notion is supported by various genetic mouse models that demonstrate an oncogenic activity of Skp2 and its requirement in cancer progression, suggesting that Skp2 may be a novel and attractive therapeutic target for cancers.…”
Get full text

Long Non-coding RNA: Characterizing the Locus Features by the Approaches by Mohammadreza Hajjari, Saghar Rahnama

“…HOTAIR is an lncRNA that has been known to have an oncogenic role in different cancers. There is limited knowledge of genetic and epigenetic elements and their interactions for the gene encoding HOTAIR. …”
Get full text

How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications by Catherine E. Bond, Vicki L. J. Whitehall

“…The BRAF oncogene is an integral component of the MAP kinase pathway, and an activating V600E mutation occurs in 15% of sporadic colorectal cancer. …”
Get full text

Long-term survival with pemetrexed-based chemotherapy in a patient with metastatic lung adenocarcinoma of unclear primary origin harboring MTHFR C677T(T/T) mutation: a case report by Yuan Yu, Yuan Yu, Yuan Yu, Nan-Jing Li, Nan-Jing Li, Nan-Jing Li, Nan-Jing Li, Jin Wang, Jin Wang, Jin Wang, Jin Wang

“…Sequential gene tests showed kirsten rat sarcoma viral oncogene homolog (KRAS) G13D mutation and epidermal growth factor receptor (EGFR) 19ins. …”
Get full text

Identification of a novel TOP2B::AFF2 fusion gene in B-cell acute lymphoblastic leukemia by Tao Liu, Yang Wang, Xi-Zhou An, Jiaqi Liu, Yuqin Wu, Yan Xiang, Yong-Jie Zhang, Lan Huang, Jia-Cheng Li, Yu-Zhuo-Pu Li, Jie Yu

“…This study identifies TOP2B::AFF2 as a potential oncogenic driver. However, further validation through in vivo studies are warranted to fully elucidate the fusion gene’s role in leukemogenesis.…”
Get full text

Occult hepatitis B virus infection: risk for a blood supply, but how about individuals’ health? by Michael X. Fu, Ahmed Elsharkawy, Brendan Healy, Celia Jackson, Daniel Bradshaw, Emma Watkins, Ines Ushiro-Lumb, Jaisi Griffiths, James Neuberger, Kathryn Maguire, Monica Desai, Neil McDougall, Nicole Priddee, Stephen T. Barclay, Stuart Blackmore, Peter Simmonds, William L. Irving, Heli Harvala

“…Following extensive multidisciplinary discussions, experts agree upon a need for clear messaging for donors and to consider the oncogenic implications of OBI. Proposals for future studies are identified, and the applicability of the recommendations in low-resource, high-endemic regions is considered, as well as the inclusion of OBI in global hepatitis elimination targets.…”
Get full text

Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53 by Iulianna C. Taritsa, Eric T. Fossel

“…However, the approach has faced numerous barriers to clinical efficacy due to several factors: mutations in p53 occur in almost half of all human cancers, mutations are cancer-specific, and the associated genomic changes grant mutant p53 with oncogenic potential unique from that of wild-type p53. …”
Get full text

Molecular Pathogenesis of MALT Lymphoma by Katharina Troppan, Kerstin Wenzl, Peter Neumeister, Alexander Deutsch

“…There is now increasing evidence suggesting that the oncogenic product of translocation cooperates with immunological stimulation in oncogenesis, that is, the association with chronic bacterial infection or autoaggressive process. …”
Get full text

Reprogramming of Mice Primary Hepatocytes into Insulin-Producing Cells by Transfection with Multicistronic Vectors by Haizhao Luo, Rongping Chen, Rui Yang, Yan Liu, Youping Chen, Yi Shu, Hong Chen

“…In the present study, we explored a novel protocol that reprogrammed primary hepatocytes into functional IPCs by using multicistronic vectors carrying pancreatic and duodenal homeobox-1 (Pdx1), neurogenin 3 (Ngn3), and v-musculoaponeurotic fibrosarcoma oncogene homolog A (MafA). These triple-transfected cells activated multiple beta-cell genes, synthesized and stored considerable amounts of insulin, and released the hormone in a glucose-regulated manner in vitro. …”
Get full text

Wnt5a Signaling in Normal and Cancer Stem Cells by Yan Zhou, Thomas J. Kipps, Suping Zhang

“…Moreover, the aberrant activation or inhibition of Wnt5a signaling is emerging as an important event in cancer progression, exerting both oncogenic and tumor suppressive effects. Recent studies show the involvement of Wnt5a signaling in regulating normal and cancer stem cell self-renewal, cancer cell proliferation, migration, and invasion. …”
Get full text

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report by Jialin Qian, Tianqing Chu

“…Background: Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). …”
Get full text

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer by Andrea L. A. Wong, Soo-Chin Lee

“…HER2-positive breast cancers have poorer prognosis and are prime candidates for molecular-targeted therapy because they are driven by the unique mechanism of HER2 oncogene addiction. While anti-HER2 agents such as trastuzumab and lapatinib are integral to the treatment of HER2-positive breast cancer, intrinsic and secondary resistance pose a significant challenge, underscoring the need to develop novel anti-HER2 therapies. …”
Get full text